Pre-earnings brief
Reports
Mon, May 4, 2026
Est. EPS
$-0.08
Est. revenue
$160M
Implied move
±3.8%
EPS beat rate
88%
Amicus Therapeutics, Inc. is a biotechnology company focused on developing therapies for rare genetic diseases. With a market cap of $5 billion, it plays a significant role in the healthcare sector, particularly in addressing unmet medical needs in rare diseases.
Last quarter
In Q4-2025, Amicus reported an EPS of $0.10, exceeding expectations by 49.25%. However, the stock experienced a slight decline of 0.07% the following day.
EPS beat streak
7Q
EPS beat rate
88%
Avg EPS surprise
+157.80%
Avg 1-day reaction
-1.80%
Analysts are anticipating a loss of $0.08 per share on revenues of $160 million for Q1-2026. Given the company's recent performance, expectations are mixed.
Bull case
If Amicus can beat the EPS estimate and show strong revenue growth, it could signal a positive trend in its product pipeline and market acceptance.
Bear case
Conversely, if the company fails to meet expectations, it may raise concerns about its financial stability and future growth prospects.
Key metrics to watch
EPS
$-0.08Earnings per share (EPS) is a critical measure of profitability and reflects the company's ability to generate earnings.
Revenue
$160MRevenue indicates the company's sales performance and overall market demand for its products.
The print will turn on these.
Q1
Will Amicus achieve revenue of at least $160 million this quarter?
Meeting or exceeding this revenue target will be crucial for demonstrating growth and market demand for its therapies.
Q2
Can the company maintain or improve its EPS performance compared to the consensus estimate?
A better-than-expected EPS could indicate improved operational efficiency and profitability, which is vital for investor confidence.
Why consensus could be wrong
The Street may be underestimating Amicus's ability to leverage its recent product developments, which could lead to better-than-expected revenue.
Supporting evidence
The company has a strong track record of beating EPS estimates, with an 88% success rate in the last eight quarters.
Options are pricing a smaller move than historical averages, suggesting the market may not fully account for potential upside.
Recent product advancements may not be reflected in current revenue expectations.
Key risk
If revenue comes in significantly above $160 million, it could challenge current bearish sentiments.
Pre-commit to what would confirm each case.
The market is weighing the potential for Amicus to continue its recent trend of beating EPS estimates against the backdrop of its revenue expectations.
Bull confirmed if
Achieving an EPS of $0.00 or better would confirm the bull case and suggest strong operational performance.
Bear confirmed if
An EPS of worse than $-0.08 would confirm the bear case and raise concerns about the company's financial health.
What the market is pricing for the move.
Implied Move
±3.8%
Historical Avg
±5.5%
The options market is pricing in a modest move of approximately 3.8% around the earnings announcement, suggesting uncertainty but not extreme volatility.
Options are pricing ±3.8% while FOLD has averaged ±5.5% over the last 8 prints — setup is pricing cheap.
30d HV
1.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Amicus beats expectations, history suggests the stock could see a modest increase, confirming a positive outlook for the company's growth.
In line / cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future performance.
Miss
A miss on earnings could lead to a decline in the stock, with historical patterns indicating an average drop of around 6.5%.
The lines on the call that would change the story.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%